Syndromes affecting the heart

AngelMed Announces First Commercial Implantation of Real-Time Heart Attack Warning System

Retrieved on: 
Tuesday, July 27, 2021
Medicine, Medical technology, Branches of biology, Medical emergencies, Biomedical engineering, Prosthetics, Acute coronary syndrome, Syndromes affecting the heart, Implant

Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.

Key Points: 
  • Indicated for acute coronary syndrome (ACS) events, including silent heart attacks, The Guardian Systemis the first implantable cardiac detection monitor and patient-warning system.
  • Dr. Kaplan is a pioneer of new cardiac technologies and has played a significant role in The Guardian's commercialization.
  • "The first commercial implant of The Guardian marks a pivotal advancement in cardiac care.
  • The device detects impending ACS events, including silent heart attacks, and leads to earlier patient treatment," said Dr. Andrew Kaplan.

Individual With Down Syndrome Testifies For Phasing Out Subminimum Wages For Individuals With Disabilities

Retrieved on: 
Wednesday, July 21, 2021
Down syndrome, Syndromes, Branches of biology, Clinical medicine, National Down Syndrome Society, Syndromes affecting the heart, Disability, NDSS

Mr. Anton, who works as MDSC'slegislative specialist, has been a vocal advocate on issues concerning the rights of individuals with Down syndrome.

Key Points: 
  • Mr. Anton, who works as MDSC'slegislative specialist, has been a vocal advocate on issues concerning the rights of individuals with Down syndrome.
  • While working for subminimum wages, he was bored and asked his boss for more work.
  • Phasing out 14(c) will help pave the way for equality in the workplace for people with Down syndrome and other disabilities."
  • The National Down Syndrome Society (NDSS) is the leading human rights organization for all individuals with Down syndrome.

GLOBAL Applauds House Appropriations Subcommittee for Approving $15 Million Increase for NIH INCLUDE Initiative and Related Down Syndrome Research as Part of FY2022 Budget

Retrieved on: 
Tuesday, July 13, 2021
Clinical medicine, Branches of biology, Syndromes affecting the heart, Medicine, Chromosomal abnormalities, Down syndrome, Intellectual disability, Prenatal testing

The INCLUDE Initiative has been a resounding success, run out of the Office of the NIH Director with support from NIH Champions Drs.

Key Points: 
  • The INCLUDE Initiative has been a resounding success, run out of the Office of the NIH Director with support from NIH Champions Drs.
  • The Global Down Syndrome Foundation (GLOBAL) is the largest non-profit in the U.S. working to save lives and dramatically improve health outcomes for people with Down syndrome.
  • Working closely with Congress and the National Institutes of Health, GLOBAL is the lead advocacy organization in the U.S. for Down syndrome research and medical care.
  • GLOBAL's widely circulated medical publications include GLOBAL Medical Care Guidelines for Adults with Down Syndrome, Prenatal Testing and Information about Down Syndrome , and the award-winning Down Syndrome WorldTM magazine.

AngelMed Announces FDA Approval of the Enhanced Real-Time Cardiac Monitor for Acute Coronary Syndrome (ACS) Events

Retrieved on: 
Monday, June 28, 2021
Circulatory system, Cardiovascular system, Medical emergencies, Syndromes affecting the heart, Branches of biology, Acute coronary syndrome, Cardiology, Heart, Cardiac electrophysiology, Neuroprosthetics, Outline of cardiology, Cardiac stress test

The AngelMed Guardian System is the world's first implantable cardiac detection monitor and patient-warning system for acute coronary syndrome (ACS) events, including silent heart attacks.

Key Points: 
  • The AngelMed Guardian System is the world's first implantable cardiac detection monitor and patient-warning system for acute coronary syndrome (ACS) events, including silent heart attacks.
  • "The improved AngelMed Guardian devicewill have a meaningful effect on the current standard of patient cardiology care for ACS events.
  • Angel Medical Systems maintains a robust portfolio of U.S. patents relating to detecting cardiac events, including silent heart attacks.
  • Implanted monitor alerting to reduce treatment delay in patients with acute coronary syndrome events.

Global Dry Eye Syndrome Market Report 2021: Market Reached a Value of $3.9 Billion in 2020 - Industry Trends, Share, Size, Growth, Opportunity and Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 19, 2021
General Health, Other Health, Health, Optical, Managed care, Organ systems, Clinical medicine, Health, Genetic syndromes, Down syndrome, Intellectual disability, Syndromes affecting the heart, Dry eye syndrome

b'The "Dry Eye Syndrome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global dry eye syndrome market reached a value of US$ 3.9 Billion in 2020.

Key Points: 
  • b'The "Dry Eye Syndrome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global dry eye syndrome market reached a value of US$ 3.9 Billion in 2020.
  • What is the global dry eye syndrome market breakup by disease type?\n7.
  • What is the global dry eye syndrome market breakup by drug type?\n8.
  • What are the major regions in the global dry eye syndrome market?\nBased on the disease type, evaporative dry eye syndrome currently accounts for the highest market share.\n'

People with Down Syndrome Set a GUINNESS WORLD RECORDS™ Title

Retrieved on: 
Friday, April 9, 2021
Branches of biology, Medicine, Syndromes, Syndromes affecting the heart, Down syndrome, Intellectual disability, Syndrome

"Global Down Syndrome Foundation and Down Syndrome Association of Ontario are proud to be able to tell the world that a dedicated group of people with Down syndrome have set a GUINNESS WORLD RECORDS title," says Michelle Sie Whitten, President & CEO of Global Down Syndrome Foundation.

Key Points: 
  • "Global Down Syndrome Foundation and Down Syndrome Association of Ontario are proud to be able to tell the world that a dedicated group of people with Down syndrome have set a GUINNESS WORLD RECORDS title," says Michelle Sie Whitten, President & CEO of Global Down Syndrome Foundation.
  • "We are grateful to Guinness World Records for giving us this opportunity," says Domenic Gentilini, Chair of the Down Syndrome Association of Ontario.
  • Key sponsors included:Down Syndrome Connection of the Bay Area, Down Syndrome Association of Peel, Down Syndrome Association National Capital Region, Down Syndrome Association of York Region, Down Syndrome Association of Brantford, Waterloo Down Syndrome Association, Down Syndrome Association Simcoe County, Down Syndrome Association of Peterborough, Down Syndrome Guild of Greater Kansas City, and RE/MAX.
  • "I was happy to support GLOBAL, DSAO and of course win a GUINNESS WORLD RECORDS title!"

Dup15q Syndrome Market Expected to Experience Steady Growth at a CAGR of 23.96% During the Study Period 20170-30 in the 7MM, says DelveInsight

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Clinical medicine, Medicine, Dup15q, Syndromes affecting the heart, Sjögren syndrome, Market, Down syndrome

Further, the Dup15q Syndrome market size of symptomatic therapies is expected to continue to increase throughout the study period.

Key Points: 
  • Further, the Dup15q Syndrome market size of symptomatic therapies is expected to continue to increase throughout the study period.
  • Soticlestat will enter the US Dup15q Syndrome market in 2024 and the EU and Japan Dup15q Syndrome market in 2025.
  • The Dup15q Syndrome market size in the US was estimated to be USD 9.84 million in 2020 and is expected to rise in the forecast period.
  • Get comprehensive insights @ Dup15q Syndrome Market Landscape, Epidemiological Insights, and Pipeline Therapies
    The Dup15q Syndrome market report offers a detailed analysis of treatment landscape, emerging therapies, changing market landscape, individual market share of pipeline therapies, Dup15q Syndrome market drivers, and market barriers, Dup15q Syndrome market size during the study period 2017-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).

Dup15q Syndrome Market Expected to Experience Steady Growth at a CAGR of 23.96% During the Study Period 20170-30 in the 7MM, says DelveInsight

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Clinical medicine, Medicine, Dup15q, Syndromes affecting the heart, Sjögren syndrome, Market, Down syndrome

Further, the Dup15q Syndrome market size of symptomatic therapies is expected to continue to increase throughout the study period.

Key Points: 
  • Further, the Dup15q Syndrome market size of symptomatic therapies is expected to continue to increase throughout the study period.
  • Soticlestat will enter the US Dup15q Syndrome market in 2024 and the EU and Japan Dup15q Syndrome market in 2025.
  • The Dup15q Syndrome market size in the US was estimated to be USD 9.84 million in 2020 and is expected to rise in the forecast period.
  • Get comprehensive insights @ Dup15q Syndrome Market Landscape, Epidemiological Insights, and Pipeline Therapies
    The Dup15q Syndrome market report offers a detailed analysis of treatment landscape, emerging therapies, changing market landscape, individual market share of pipeline therapies, Dup15q Syndrome market drivers, and market barriers, Dup15q Syndrome market size during the study period 2017-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).

Albireo Announces First Patients Dosed in Two New Studies

Retrieved on: 
Thursday, March 25, 2021
Medical specialties, Clinical medicine, Digestive diseases, Hepatology, Alagille syndrome, Ciliopathy, Syndromes affecting the heart, Autoimmune diseases, Syndromes, Sjögren syndrome

Additionally, the Company enrolled its first patient in the ASSERT Study, a global Phase 3 pivotal trial of odevixibat in patients with Alagille syndrome (ALGS).

Key Points: 
  • Additionally, the Company enrolled its first patient in the ASSERT Study, a global Phase 3 pivotal trial of odevixibat in patients with Alagille syndrome (ALGS).
  • I am proud of the work and great progress we are making in our studies of odevixibat in rare cholestatic diseases, said Patrick Horn, Chief Medical Officer of Albireo.
  • An additional exploratory cohort of patients 18 years of age with genetically confirmed diagnosis will be enrolled, not to exceed 18 patients in total.
  • As a result of risks and uncertainties that Albireo faces, the results or events indicated by any forward-looking statement may not occur.

Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

Retrieved on: 
Friday, March 19, 2021
Medical specialties, Clinical medicine, Medicine, Intensive care medicine, Hypoplastic left heart syndrome, Syndromes affecting the heart, Stock market, Respiratory distress syndrome, HLHS, Ards, Acute respiratory distress syndrome, Infant respiratory distress syndrome

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

Key Points: 
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.
  • To request complimentary investor registration: please visit our website at www.investorsummitgroup.com
    Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions.
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).